Literature DB >> 28011152

Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity.

Elisa Alchera1, Simona Rolla2, Chiara Imarisio1, Valentina Bardina2, Guido Valente3, Francesco Novelli4, Rita Carini5.   

Abstract

Lipotoxicity and immunoinflammation are associated with the evolution of steatosis toward nonalcoholic steatohepatitis (NASH). This study reports the ability of adenosine A2a receptor (A2aR) activation to inhibit NASH development by modulating the responses of CD4+ T-helper (Th) cells to avoid an immuno-mediated potentiation of lipotoxicity. The effect of the A2aR agonist CGS21680 on immunoinflammatory signals, CD4+Th cell infiltration and immunolipotoxicity was analyzed in steatotic C57BL/6 mice fed with a methionine-choline-deficient (MCD) diet and in mouse hepatocytes exposed to palmitic acid (PA). CGS21680 inhibited NASH development in steatotic mice and decreased cytokines and chemokines involved in Th cell recruitment or polarization (namely CXCL10, CCL2, tumor necrosis factor alfa [TNFα], tumor growth factor [TGFβ], and IL-12). CGS21680 also reduced the expansion of Th17, Th22, and Th1 cells and increased the immunosuppressive activity of T regulatory cells. In PA-treated mice hepatocytes, CGS21680 inhibited the production of CXCL10, TNFα, TGFβ, IL-12, and CCL2; CGS21680 also prevented JNK-dependent lipotoxicity and its intensification by IL-17 or IL-17 plus IL-22 through Akt/PI3-kinase stimulation and inhibition of the negative regulator of PI3-kinase, (phosphatase and tensin homologue deleted from chromosome 10 (PTEN), which is upregulated by IL-17. In MCD livers, CGS21680 reduced JNK activation and PTEN expression and increased Akt phosphorylation. In conclusion, A2aR stimulation inhibited NASH development by reducing Th17 cell expansion and inhibiting the exacerbation of the IL-17-induced JNK-dependent lipotoxicity. These data promote the implementation of further studies to evaluate the potential clinical application of A2aR agonists that, by being able to function as both cytoprotective and immunomodulatory agents, could efficiently antagonize the multi-faced pathogenesis of NASH.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28011152     DOI: 10.1016/j.trsl.2016.11.009

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  10 in total

1.  Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity.

Authors:  Yuli Cai; Honggui Li; Mengyang Liu; Ya Pei; Juan Zheng; Jing Zhou; Xianjun Luo; Wenya Huang; Linqiang Ma; Qiuhua Yang; Shaodong Guo; Xiaoqiu Xiao; Qifu Li; Tianshu Zeng; Fanyin Meng; Heather Francis; Shannon Glaser; Lulu Chen; Yuqing Huo; Gianfranco Alpini; Chaodong Wu
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

2.  Regulation of adipose tissue inflammation by adenosine 2A receptor in obese mice.

Authors:  Ya Pei; Honggui Li; Yuli Cai; Jing Zhou; Xianjun Luo; Linqiang Ma; Kelly McDaniel; Tianshu Zeng; Yanming Chen; Xiaoxian Qian; Yuqing Huo; Shannon Glaser; Fanyin Meng; Gianfranco Alpini; Lulu Chen; Chaodong Wu
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

Review 3.  Purinergic Signaling in Liver Pathophysiology.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-11       Impact factor: 5.555

Review 4.  ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism.

Authors:  Jing Li; Han Yan; Rui Xiang; Weili Yang; Jingjing Ye; Ruili Yin; Jichun Yang; Yujing Chi
Journal:  Front Physiol       Date:  2022-06-21       Impact factor: 4.755

5.  Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH.

Authors:  Jing Zhou; Honggui Li; Yuli Cai; Linqiang Ma; Destiny Mathews; Bangchao Lu; Bilian Zhu; Yanming Chen; Xiaoxian Qian; Xiaoqiu Xiao; Qifu Li; Shaodong Guo; Yuqing Huo; Liang Zhao; Yanan Tian; Qingsheng Li; Chaodong Wu
Journal:  J Endocrinol       Date:  2019-09-01       Impact factor: 4.286

Review 6.  Purinergic signaling in diabetes and metabolism.

Authors:  Shanu Jain; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2020-12-25       Impact factor: 5.858

Review 7.  Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity.

Authors:  Patricia Lamadrid; Marta Alonso-Peña; David San Segundo; Mayte Arias-Loste; Javier Crespo; Marcos Lopez-Hoyos
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

8.  PTEN: A Thrifty Gene That Causes Disease in Times of Plenty?

Authors:  Ajit Venniyoor
Journal:  Front Nutr       Date:  2020-06-05

9.  Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.

Authors:  Tian Lan; Yang Yu; Jing Zhang; Haonan Li; Qiqing Weng; Shuo Jiang; Song Tian; Tonghao Xu; Sha Hu; Guizhi Yang; Yan Zhang; Weixuan Wang; Lexun Wang; Qing Zhu; Xianglu Rong; Jiao Guo
Journal:  Hepatology       Date:  2021-08       Impact factor: 17.425

Review 10.  Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease.

Authors:  Xiaoxiao Wang; Huiying Rao; Feng Liu; Lai Wei; Honggui Li; Chaodong Wu
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.